![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
Active Filter(s):
Details:
Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths approved for sale in the Canadian market by the Pharmaceutical Drugs Directory (PDD) of Health Canada.
Lead Product(s): Desvenlafaxine Succinate
Therapeutic Area: Psychiatry/Psychology Product Name: Desvenlafaxine-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Intellipharmaceutics Corp.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 16, 2022